Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches
Frontiers in Pharmacology · 17.11.2026 · 17
DOI: 10.3389/fphar.2026.2030892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.11.2026. Verfasst von Jindong Dai und 8 weiteren Autor:innen. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic kidney disease (CKD) is increasingly recognised as a systemic disorder in which a bidirectional host–microbiota relationship contributes to disease progression. This review is deliberately restricted in scope to the microbial metabolites for which mechanistic and clinical evidence is most developed: the protein-bound uremic solutes indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), and the microbiota-derived co-metabolite trimethylamine N-oxide (TMAO). These harmful metabolites are explicitly contrasted with short-chain fatty acids (SCFAs), the principal class of beneficial microbial metabolites, whose depletion represents a loss of reno-protection rather than a gain of toxicity. In CKD, the colonic milieu is reshaped by urea influx, restricted fruit, vegetable and fibre intake, slowed intestinal transit and repeated antibiotic and phosphate-binder exposure; the resulting dysbiosis favours proteolytic fermentation and the generation of indole and p-cresol, which undergo hepatic and intestinal phase II conjugation to IS and p-CS, while choline- and carnitine-derived trimethylamine is oxidised by hepatic flavin monooxygenase 3 to TMAO. Because these solutes are highly protein-bound, they are poorly cleared by conventional haemodialysis and accumulate as renal function declines. At the molecular level, IS is a well-characterised (AhR), and AhR activation, NADPH-oxidase-derived reactive oxygen species, NF-κB-dependent cytokine transcription and TGF-β1/Smad3-driven matrix deposition together form the best-supported injury cascade; other links, notably metabolite-directed epigenetic remodelling, remain hypothesis-generating. Therapeutic strategies are appraised according to their development stage and the strength of the evidence behind them, from the oral adsorbent AST-120 - whose pivotal EPPIC trials did not meet their primary endpoint - through investigational microbial enzyme inhibitors to experimental AhR antagonists. We argue that the field’s central unmet need is not further descriptive mechanistic work but biomarker-enriched, adequately powered and earlier-initiated clinical trials capable of distinguishing metabolite lowering from clinical benefit.
Zitieren
APA
Dai, J., Tang, X., S, S., Zou, Y., Rajalakshmi, K., Murugesan, V., Muthusamy, S., Theivendren, P., & Zhu, D. (2026). Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2030892
Vancouver
Dai J, Tang X, S S, Zou Y, Rajalakshmi K, Murugesan V, et al. Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2030892
BibTeX
@article{Dai2026,
author = {Dai, Jindong and Tang, Xiaohua and S, Sathyamoorthi and Zou, Yuerong and Rajalakshmi, Kanagaraj and Murugesan, Vijayakumar and Muthusamy, Selvaraj and Theivendren, Panneerselvam and Zhu, Dongwei},
title = {Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2030892}
}
EUVIMED